Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1981 December; 44(6): 911–916.
PMCID: PMC2010858

Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast.


Oestrogen (RE) and progesterone (RP) cytosolic receptors have been studied in 59 clinically inflammatory tumours of the human breast. The results were compared to those obtained in a series of 496 operable tumours. A single saturating dose of oestradiol for RE and R 5020 for RP was used and the cut-off between negative and positive tumours was 100 fmol/g tissue. A significant difference was seen (P less than 0.02) between the 2 classes of patients: (RE-, RP-) tumours were commoner among clinically inflammatory tumours (48%) than among operable ones (28%), independently of menopause. Concerning the histological type (based on an assessment of differentiation) and the histological grading (Scarff and Bloom) there was a significant difference (P less than 0.001) between the 2 populations of tumours. No significant difference was found in the distribution of RE and RP among the 3 histological types, whereas a significant correlation existed between histological grading and RE (P less than 0.02). Finally, patients with RE+ clinically inflammatory tumours constitute a lower risk group, especially when they are free of metastases at the time of diagnosis. The presence of RE therefore seems to indicate, as in the operable tumour group, a favourable prognosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (848K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blamey RW, Bishop HM, Blake JR, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. [PubMed]
  • BLOOM HJG. Prognosis in carcinoma of the breast. Br J Cancer. 1950 Sep;4(3):259–288. [PMC free article] [PubMed]
  • BLOOM HJ, RICHARDSON WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. [PMC free article] [PubMed]
  • BOYD JT, DOLL R. Gastro-intestinal cancer and the use of liquid paraffin. Br J Cancer. 1954 Jun;8(2):231–237. [PMC free article] [PubMed]
  • Contesso G, Rouéssé J, Petit JY, Mouriesse H. Les facteurs anatomo-pathologiques du pronostic des cancers du sein. Bull Cancer. 1977;64(4):525–536. [PubMed]
  • Cooke T, George D, Shields R, Maynard P, Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979 May 12;1(8124):995–997. [PubMed]
  • Fletcher WS, Leung BS, Davenport CE. The prognostic significance of estrogen receptors in human breast cancer. Am J Surg. 1978 Mar;135(3):372–374. [PubMed]
  • Furmanski P, Saunders DE, Brooks SC, Rich MA. The prognostic value of estrogen receptor determinations in patients with primary breast cancer: an update. Cancer. 1980 Dec 15;46(12 Suppl):2794–2796. [PubMed]
  • Hilf R, Feldstein ML, Gibson SL, Savlov ED. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer. 1980 Apr 15;45(8):1993–2000. [PubMed]
  • Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B. The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer. 1980 Dec 15;46(12 Suppl):2797–2800. [PubMed]
  • Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975 Aug 29;189(4204):726–727. [PubMed]
  • King RJ. Analysis of estradiol and progesterone receptors in early and advanced breast tumors. Cancer. 1980 Dec 15;46(12 Suppl):2818–2821. [PubMed]
  • Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed]
  • Lacour J, Hourtoule FG. La place de la chirurgie dans le traitement des formes évolutives du cancer du sein. Mem Acad Chir (Paris) 1967 Jun 14;93(19):635–643. [PubMed]
  • Martin PM, Jacquemier J, Rolland PH, Rolland AM, Toga M. Tumeurs mammaires humaines: corrélations entre les récepteurs hormonaux stéroïdiens et l'anatomie pathologique. Une hypothèse: valeur pronostique des récepteurs hormonaux. Bull Cancer. 1978;65(4):383–387. [PubMed]
  • May-Levin F, Guerinot F, Contesso G, Delarue JC, Bohuon C. Etude des récepteurs cytosoliques oestrogènes et progestogènes dans les carcinomes mammaires. Int J Cancer. 1977 Jun 15;19(6):789–795. [PubMed]
  • Maynard PV, Davies CJ, Blamey RW, Elston CW, Johnson J, Griffiths K. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer. 1978 Dec;38(6):745–748. [PMC free article] [PubMed]
  • McCarty KS, Jr, Barton TK, Fetter BF, Woodard BH, Mossler JA, Reeves W, Daly J, Wilkinson WE, McCarty KS., Sr Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer. 1980 Dec 15;46(12 Suppl):2851–2858. [PubMed]
  • Meyer JS, Rao BR, Stevens SC, White WL. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer. 1977 Nov;40(5):2290–2298. [PubMed]
  • Millis RR. Correlation of hormone receptors with pathological features in human breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2869–2871. [PubMed]
  • Osborne CK, Yochmowitz MG, Knight WA, 3rd, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. [PMC free article] [PubMed]
  • Sarrazin D, Rouëssé J, Arriagada R, May-Levin F, Petit JY, Contesso G. Les cancers du sein en "poussée évolutive". Rev Prat. 1978 Mar 1;28(13):999–1009. [PubMed]
  • Silverstrini R, Daidone MG, Di Fronzo G. Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer. 1979 Aug;44(2):665–670. [PubMed]
  • Wittliff JL, Beatty BW, Savlov ED, Patterson WB, Cooper RA., Jr Estrogen receptors and hormone dependency in human breast cancer. Recent Results Cancer Res. 1976;(57):59–77. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK